Criteria for BBB+ drugs (i.e., “good” CNS penetration.) | ||
---|---|---|
Broccatelli et al. | Kikuchi et al. | |
Marketed CNS agents | Yes | Can be misleading |
Unbound brain-to-plasma ratio | >0.1 | >0.33 |
Unbound CSF-to-plasma ratio | >0.1 | Can be misleading |
In vivo P-gp ER | Not considered | <3.0 |